Skip to content
value.today

CalciMedica, Inc.

CALC
$12 Mmarket cap on Oct 30, 2026
Compare
World rank
#25,531
Revenue
—
For year ending December-2025
Net income
$-30 M
SEC filing
Employees
16
As of December 31, 2025
value.today research

CalciMedica, Inc. in brief

CalciMedica, Inc. is a listed company in the Biotechnology industry, based in California, USA. Its market value was $12 M on 30 October 2026, which makes it the 25,531st largest listed company in the world and the 4,261st largest in the USA on this site. It employs about 16 people and A. Rachel Leheny is its chief executive. Its shares trade under the symbol CALC (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About CalciMedica, Inc.

Graybug Vision is a Clinical Stage Biopharmaceutical company focused on developing transformative medicines for the treatment of chronic diseases of the retina and optic nerve. It is having 37 employees as on 2020. The headquarters is in USA.

CalciMedica, Inc. timeline

7 events, 2011–2023
  1. 2011
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2014
  4. ✎
    Renamed GRAYBUG, Inc.
    Formerly Graybug Llc.
  5. 2016
  6. ✎
    Renamed Graybug Vision, Inc.
    Formerly GRAYBUG, Inc..
  7. 2020
  8. 🔔
    · approximate
    Initial public offering on Nasdaq
  9. 🔔
    Initial public offering as Graybug Vision, Inc.
    Final prospectus filed with the SEC on 25 September 2020; shares registered for exchange trading on 21 September 2020.
  10. 2023
  11. ✎
    Renamed CalciMedica, Inc. /DE/
    Formerly Graybug Vision, Inc..
  12. ✎
    Renamed CalciMedica, Inc.
    Formerly CalciMedica, Inc. /DE/.

Events of CalciMedica, Inc. from SEC EDGAR and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$164 M$329 M$493 M$658 M202120222023202420252026

World rank over time

▼ down 15,317 places since 2021
2021-01-01: #10228#10,22820212022-01-07: #27390#27,39020222022-12-25: #31265#31,26520222026-10-13: #26198#26,19820262026-10-30: #25545#25,5452026

Rank in USA: #2,595 (Jan 2021) · #5,095 (Jan 2022) · #5,529 (Dec 2022) · #4,282 (Oct 2026) · #4,264 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
—
Price / book
—
Free cash flow yield
-175.7%
Net margin
—
Operating margin
—
Return on equity
—
Liabilities / assets
148.9%
Profit per employee
$-1.8 M

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2019: revenue —, net income $-37M—FY19Fiscal year ending Dec 2020: revenue —, net income $-28M—FY20Fiscal year ending Dec 2021: revenue —, net income $-36M—FY21Fiscal year ending Dec 2022: revenue —, net income $-8M—FY22Fiscal year ending Dec 2023: revenue —, net income $-34M—FY23Fiscal year ending Dec 2024: revenue —, net income $-14M—FY24Fiscal year ending Dec 2025: revenue —, net income $-30M—FY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025——$-23M$-30M—
Dec 2024——$-24M$-14M—
Dec 2023——$-38M$-34M—
Dec 2022——$-14M$-8M—
Dec 2021——$-36M$-36M—
Dec 2020——$-30M$-28M—
Dec 2019——$-38M$-37M—

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-21M$0M$-21M$-1.97—
Dec 2024$-21M$0M$-21M$-1.22—
Dec 2023$-26M$0M$-26M$-7.66—
Dec 2022$-12M$0M$-12M$-111.16—
Dec 2021$-32M$0M$-32M$-1.69—
Dec 2020$-32M$1M$-33M$-5.25—
Dec 2019$-31M$1M$-32M$-33.41—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-4M—Dec ’24Three months to Mar 2025: revenue —, net income $-5M—Mar ’25Three months to Jun 2025: revenue —, net income $-6M—Jun ’25Three months to Sep 2025: revenue —, net income $-8M—Sep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-11M—Dec ’25Three months to Mar 2026: revenue —, net income $5M—Mar ’26Three months to Jun 2026: revenue —, net income $-8M—Jun ’26Three months to Sep 2026: revenue —, net income $-2M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-2M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of CalciMedica, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
—
Operating income
$-23 M
Net income
$-30 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$14 M
Total liabilities
$20 M
Total equity
$-7 M

As of December-2025

Top 17 institutional investors in CalciMedica, Inc.#

As of Sep 30, 2026
17 institutions held 1.7 M shares (about 24.5% of the shares outstanding) on Sep 30, 2026. The ten largest hold 24.5%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 17 largest institutional investors in CalciMedica, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Woodline Partners LP497,945New7.22%$1 MNov 16, 2026
2Armistice Capital, LLC388,641New5.64%$1 MNov 16, 2026
3Stonepine Capital Management, LLC278,680New4.04%$0 MNov 13, 2026
4Stempoint Capital LP248,972New3.61%$0 MNov 16, 2026
5Heights Capital Management, Inc163,728New2.37%$0 MNov 16, 2026
6Renaissance Technologies LLC47,980New0.70%$0 MNov 12, 2026
7Geode Capital Management, LLC25,437New0.37%$0 MNov 6, 2026
8Cambridge Investment Research Advisors, Inc.16,450New0.24%$0 MNov 2, 2026
9Jane Street Group, LLC15,000New0.22%$0 MNov 12, 2026
10Rockefeller Capital Management L.P.4,000New0.06%$0 MNov 13, 2026
11Tower Research Capital LLC (TRC)2,535New0.04%$0 MNov 16, 2026
12Jpmorgan Chase & Co2,444New0.04%$0 MNov 12, 2026
13Brown Brothers Harriman & Co60New0.00%$0 MNov 13, 2026
14Osaic Holdings, Inc.21New0.00%$0 MNov 12, 2026
15SBI Securities Co., Ltd.17New0.00%$0 MOct 22, 2026
16Wells Fargo & Company/mn2New0.00%$0 MNov 16, 2026
17UBS Group AG2New0.00%$0 MNov 10, 2026

Insider trading at CalciMedica, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$199 K
1 purchase, 1 insider
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$199 K
open market only
Insiders on file
24
since
$2.5 M-$4 K$0Nov 2023: bought $202 K (9 trades), sold $0 (0 trades)Nov 23Dec 2023: bought $2 K (1 trades), sold $0 (0 trades)Jan 2024: bought $2.5 M (14 trades), sold $0 (0 trades)Jan 24Apr 2024: bought $16 K (2 trades), sold $0 (0 trades)Jun 2024: bought $224 K (3 trades), sold $0 (0 trades)JunAug 2024: bought $243 K (5 trades), sold $0 (0 trades)Nov 2024: bought $604 K (8 trades), sold $0 (0 trades)NovDec 2024: bought $13 K (1 trades), sold $0 (0 trades)May 2025: bought $2 K (1 trades), sold $0 (0 trades)MayJun 2025: bought $36 K (5 trades), sold $0 (0 trades)Jul 2025: bought $69 K (10 trades), sold $4 K (1 trades)JulAug 2025: bought $105 K (9 trades), sold $0 (0 trades)Sep 2025: bought $40 K (4 trades), sold $0 (0 trades)SepJun 2026: bought $199 K (1 trades), sold $0 (0 trades)
Bought (open market)Sold (open market)Hover a month for the totals
CalciMedica, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Robert N. WilsonDirectorGrant or award+1.18 M$0.800$946 K1.60 MForm 4
filed Eric W. RobertsCHIEF BUSINESS OFFICER, Director, 10% ownerGrant or award+186,729$0.800$149 K366,435Form 4
filed Sudarshan HebbarChief Medical OfficerGrant or award+124,486$0.800$100 K186,025Form 4
filed Fred A. MiddletonDirector, 10% ownerBuyindirect+248,972$0.800$199 K1.06 MForm 4
filed A. Rachel LehenyCHIEF EXECUTIVE OFFICER, Director, 10% ownerGrant or award+186,729$0.800$149 K317,655Form 4
filed Eric W. RobertsCHIEF BUSINESS OFFICER, Director, 10% ownerBuyindirect+2,500$3.070$8 K84,150Form 4
filed Eric W. RobertsCHIEF BUSINESS OFFICER, Director, 10% ownerBuyindirect+3,400$2.680$9 K81,650Form 4
filed Eric W. RobertsCHIEF BUSINESS OFFICER, Director, 10% ownerBuyindirect+5,000$3.120$16 K78,250Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: CalciMedica, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
171,388
1.78 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-1 split ; 1-for-9.01 reverse split

Trading halts

  • 2026-08-28 23:50 UTC, code T3, resumed 13:00 UTC
  • 2026-01-28 15:57 UTC, code LUDP, resumed 16:02 UTC
  • 2026-01-28 15:50 UTC, code LUDP, resumed 15:55 UTC
  • 2026-01-28 15:44 UTC, code LUDP, resumed 15:49 UTC
  • 2026-01-28 15:38 UTC, code LUDP, resumed 15:43 UTC

Fails to deliver

  • : 1,372 shares at $1.75
  • : 1,638 shares at $1.66
  • : 138 shares at $1.15
  • : 3,779 shares at $1.15
  • : 658 shares at $1.21

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

CalciMedica, Inc. scorecard#

Passes 1 of the 11 checks that could be worked out. Fiscal year 2025; market cap of Oct 30, 2026.

  • Valuation0 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • ✗Free cash flow yield above 5%-175.7%Free cash flow is -175.7% of the market value.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth0 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-1.97 vs -1.22Diluted EPS -1.97 in fiscal 2025 against -1.22 the year before (report's currency).
    • ✗Net income higher than five years earlier-$30 M-$30 M in fiscal 2025 against -$28 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 2
    • ✗Profitable in the newest year-$30 MNet income -$30 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 2
    • ✓Short-term assets cover short-term liabilities3.6×Current ratio 3.58 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year33.5%Diluted shares up 33.5% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

CalciMedica, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

CalciMedica, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019
Income statement
Research and development1514168.4r192131
General and administrative7.99.7225.8r178.96.9
Operating expenses23243814r363038
Operating income−23−24−38−14r−36−30−38
Interest and finance income———0.60.10.10.4
Interest expense and finance costs1.40—————
Non-interest income0.71.0—————
Other non-operating income (expense)−6.4113.76.4———
Income before tax−30−14—————
Income tax000.00.0———
Net income including minority interests−30−14−34−7.8r−36−28−37
Net income attributable to shareholders−30−14−34−7.8r−36−28−37
Earnings per share, basic-1.97-1.22-7.66-111.16r-1.69-5.25-33.41
Earnings per share, diluted-1.97-1.22-7.66-111.16r-1.69-5.25-33.41
Shares, weighted average (basic)15114.50.1r21——
Shares, weighted average (diluted)15114.50.1r216.61.3
Balance sheet
Cash and cash equivalents127.95.51.3r133316
Short-term investments1.5115.70r506220
Other current assets0.30.20.3r0.3r1.4r1.5r0.3
Current assets1420121.7r679936
Property, plant and equipment0.10.10.20.12.01.92.0
Right-of-use (leased) assets——00.0———
Total assets1420123.3r6910241
Accounts payable1.22.01.42.9r0.52.54.6
Current liabilities3.83.74.04.8r4.17.012
Total liabilities205.44.013r4.17.012
Retained earnings−189−160−146−112r−169−133−106
Shareholders' equity−6.6148.2−71r−64r95−103
Total liabilities and equity1420123.3r6910241
Shares outstanding3.1r135.80.1r21211.4
Cash-flow statement
Depreciation and amortization——0.10.1———
Share-based compensation3.02.3121.8r5.41.80.7
Cash from operating activities−21−21−26−12r−32−32−31
Capital expenditure−0.0−0.0−0.1−0.0r−0.5−1.0−0.6
Cash from investing activities9.6−4.48.9−0.0r11−43−21
Shares issued0.02810——96—
Cash from financing activities1528218.5r0.79255
Change in cash3.62.44.1−3.3r−20183.0
Report10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

Executive pay at CalciMedica, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$895 K
A. Rachel Leheny
Other top executives, average
$733 K
the CEO earned 1.2× this
$100 invested is now
$230
CalciMedica, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025A. Rachel Leheny$895 K$2.4 M$733 K$230
2024A. Rachel Leheny$1.7 M$1.5 M$1.3 M$124

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at CalciMedica, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Auditor changedFiling

Delisting notice 1 · Auditor changed 1 · Directors and officers 5 · Material agreement 3 · New debt 1 · Unregistered share sale 3 · Bylaws or fiscal year changed 1 · Shareholder vote 2 · Results announced 9

CalciMedica, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Directors and officers8-K
Bylaws or fiscal year changed8-K
Directors and officersShareholder vote8-K
Results announced8-K
Directors and officers8-K
Material agreementUnregistered share sale8-K
Material agreementUnregistered share sale8-K
Results announced8-K
Delisting notice8-K
Results announced8-K
Results announced8-K
Results announced8-K
Directors and officersShareholder vote8-K
Auditor changed8-K
Results announced8-K
Results announced8-K
Material agreementNew debtUnregistered share sale8-K
Directors and officers8-K
Results announced8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026

Acquisitions and funding#

4 private funding rounds before listing

Private share sales · funding history

Private share sales of CalciMedica, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2023$9 MPrivate placement after listing$2 to $10 million55equity, optionsSEC
Jul 2019$55 MNo. 4$50 to $250 million8equitySEC
Apr 2016$75 MNo. 3$50 to $250 million16equitySEC
Feb 2015$2 MNo. 2Under $2 million2equity, optionsSEC
Sep 2013$1 MNo. 1Under $2 million7equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at CalciMedica, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2022–2022
Latest
—
2022-08-18
CalciMedica, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2022············—
CalciMedica, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling

Source: State WARN notices and SEC 8-K item 2.05

How CalciMedica, Inc. compares in Biotechnology

  • Market cap$12 M · higher than 12% of 726
  • FCF yield-175.7% · higher than 2% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
CalciMedica, Inc.🇺🇸$12 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 30, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at CalciMedica, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show CalciMedica, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about CalciMedica, Inc.? Suggest a correction